Newsroom: Latest News
Igyxos welcomes Dr. Amir Lass, MD as Chief Medical Officer
Nouzilly, March 10, 2023 – Igyxos, a biotechnology company specializing in the treatment of infertility starting with male, is pleased to announce the appointment of Dr Amir Lass as Chief Medical Officer.
Dr Lass will provide support and leadership in the clinical development of IGX12, a novel first-in-class product for male and female infertility. With over 35 years of experience in the clinical and pharmaceutical industry, Dr Lass brings a wealth of expertise and knowledge to his new role. Dr. Lass will be in charge of the definition of the IGX12 clinical strategy in close collaboration with the CSO and the scientific committee, identifying key partners and supervising the clinical studies.
As a highly respected Medical Consultant and expert in fertility, Amir has dedicated his career to advancing clinical and pharmaceutical research in women's health and reproductive medicine. His extensive portfolio of consultancy work and senior positions have equipped him with a strong commercial acumen and a proven track record of building, integrating, motivating, and mentoring medical teams across Europe
“We are pleased to welcome Dr. Lass as our key product, IGX12, is close to reaching first-in-human milestone ” said Emmanuel Dulac, Igyxos Chief Executive Officer. “As an expert in the field, Dr Lass will provide key expertise to support IGX12 clinical development demonstrating its superiority over standard of care for male and female indications”.
About Igyxos
Igyxos is a biotechnology company building on its expertise and experience of his team to provide innovative treatment in the field of infertility. Igyxos is involved in all phases of development, from the discovery of promising targets to the identification of potential active compounds such as small molecules and antibodies. The success of its €7.5 million Series A funding led by Bpifrance, through the FABS funds, alongside with Go Capital Amorçage II and Loire Valley Invest Funds managed by Go Capital and the Emergence Innovation II Fund managed by Sofimac Innovation, will allow Igyxos to develop its lead compound, IGX12 and reach clinical proof of concept. www.igyxos.com.
Press Contacts:
Igyxos
Pierre-Henry Longeray
06 64 28 81 31
Marie-Christine Maurel
06 03 34 75 36